| For: | Suryadevara V, Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. Incretin based therapy and pancreatic cancer: Realising the reality. World J Gastroenterol 2022; 28(25): 2881-2889 [PMID: 35978867 DOI: 10.3748/wjg.v28.i25.2881] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v28/i25/2881.htm |
| Number | Citing Articles |
| 1 |
Zayed Rashid, Selamawit Woldesenbet, Mujtaba Khalil, Abdullah Altaf, Shahzaib Zindani, Areesh Mevawalla, Azza Sarfraz, Khalid Mumtaz, Timothy M. Pawlik. Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. Journal of General Internal Medicine 2026; 41(7) doi: 10.1007/s11606-026-10300-1
|
| 2 |
Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. Pancreatology 2026; 26(6) doi: 10.1016/j.pan.2026.04.005
|
| 3 |
Anqi Lin, Yanxi Ding, Zhengrui Li, Aimin Jiang, Zaoqu Liu, Hank Z. H. Wong, Quan Cheng, Jian Zhang, Peng Luo. Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence. Biomarker Research 2025; 13(1) doi: 10.1186/s40364-025-00765-3
|
| 4 |
Eric Ricardo Yonatan, Louis Fabio Jonathan Jusni, Steven Alvianto, Nicolas Daniel Widjanarko, Steven Yulius Usman, Virly Nanda Muzellina. Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis. Journal of Gastrointestinal Cancer 2025; 56(1) doi: 10.1007/s12029-025-01330-9
|
| 5 |
Udhayvir S. Grewal, Po H. Ear, Mohamad B. Sonbol, Andrew M. Bellizzi, Johannes Hofland, Joakim Crona, Joseph S. Dillon, Jennifer A. Chan, James R. Howe, Jonathan Strosberg, Simron Singh, Thorvardur R. Halfdanarson. Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement. Cancer 2026; 132(16) doi: 10.1002/cncr.70586
|
| 6 |
Carla Micaela Cuttica, Irene Maria Briata, Andrea DeCensi. Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment. Nutrients 2023; 15(17) doi: 10.3390/nu15173737
|
| 7 |
Jiaqi Wu, Liang Tang, Feng Zheng, Xun Chen, Lei Li. A review of the last decade: pancreatic cancer and type 2 diabetes. Archives of Physiology and Biochemistry 2024; 130(6) doi: 10.1080/13813455.2023.2252204
|
| 8 |
Azza O. Alawad, Tarig H. Merghani, Tarig E. Fadelelmoula, Nasir Abdelrafie Elamin, Shahenaz Satti, Alhiedi Ali Edris, Alwaleed Hakim, Rima Fathi El-Hindi, Ahmed Abdalla Alhaj-Ali, Wasil Elnour Ibrahim, Muhanad Ahmed Mustafa, Maymouna Mohieldin Sirelkhatim, Hany Hatim Ahmed, Nadia Osman Yousif. Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review. Therapeutic Advances in Endocrinology and Metabolism 2026; 17 doi: 10.1177/20420188261469947
|
| 9 |
Francesco Tassone, Giovanna Saraceno. Intraductal Papillary Mucinous Neoplasms and GLP-1 Receptor Agonists: Navigating Therapeutic Uncertainty in Diabetes Management. Biomedicines 2025; 13(10) doi: 10.3390/biomedicines13102326
|
| 10 |
Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal. Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. Cancers 2026; 18(2) doi: 10.3390/cancers18020179
|
| 11 |
Yuanyuan Zhong, Xing Tan, Ling Zhang, Cangui Wu. Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1916932
|
| 12 |
Mi Kyung Kim, Eun Yeong Ha, Hye Soon Kim. Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations. Journal of Obesity & Metabolic Syndrome 2026; 35(2) doi: 10.7570/jomes25081
|
| 13 |
Antongiulio Faggiano, Antonella Argentiero, Giulia Borghesani, Jonida Haxhi, Stefania Camastra, Saverio Cinieri, Alessio Cortellini, Marzia Del Re, Marco Gallo, Annalisa Natalicchio, Dario Giuffrida, Stefania Gori, Valerio Gristina, Matteo Monami, Lelio Mordivucci, Alberto Ragni, Cristiana Randazzo, Valerio Renzelli, Laura Sciacca, Dalila Tessitore, Maria Chiara Zatelli, Massimo Di Maio, Rocco Barazzoni, Nicola Marrano, Diego Ferone, Nicola Silvestris, Francesco Giorgino. Incretin‐Based Therapy in Patients with Malignancy and Obesity or Type 2 Diabetes. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF), and Italian Society of Obesity (SIO) Position Paper. Obesity Reviews 2026; doi: 10.1111/obr.70231
|
| 14 |
Estelle Grasset, François Briand, Nicolina Virgilio, Christiane Schön, Manfred Wilhelm, Benoit Cudennec, Rozenn Ravallec, Hairati Aboubacar, Sara Vleminckx, Janne Prawitt, Thierry Sulpice, Elien Gevaert. A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans. Food Science & Nutrition 2024; 12(11) doi: 10.1002/fsn3.4538
|
| 15 |
Victoria Carolina Barcelos Fonseca, Paula Carolina Caetano Ferreira, Phellyp Henrique Rocha Silva, Thiago Alves Moreira César, Eduardo Carvalho Garcia. Agonistas do receptor de GLP-1 e risco de pancreatite aguda: uma revisão sistemática. Cuadernos de Educación y Desarrollo 2024; 16(12 Edição Especial) doi: 10.55905/cuadv16n12-044
|
| 16 |
Neeti Agrawal, Arjun Baidya, Mainak Banerjee, Asish Kumar Basu, Rana Bhattacharjee, Sugata Narayan Biswas, Partha Pratim Chakraborty, Satyam Chakraborty, Chandan Chatterjee, Subhankar Chatterjee, Utpal Roy Chaudhuri, Partha Sarathi Choudhury, Amarta Shankar Chowdhury, Subhankar Chowdhury, Swayang Prakash Chowdhury, Niladri Das, Ranen Dasgupta, Saumik Datta, Abhranil Dhar, Piyas Gargari, Amritava Ghosh, Soumendu Ghosh, Sujoy Ghosh, Soumik Goswami, Anish Kar, Indira Maisnam, Sujoy Majumdar, Anirban Majumder, Soumita Mandal, Sunetra Mondal, Pradip Mukhopadhyay, Sarmistha Mukhopadhyay, Satinath Mukhopadhyay, Subhasis Neogi, Rajan Palui, Kaushik Pandit, Subhodip Pramanik, Arindam Ray, Moutusi Raychaudhari, Ajitesh Roy, Debmalya Sanyal, Trinanjan Sanyal, Dasarathi Sarkar, Nilanjan Sengupta, Awadhesh Kumar Singh, Anirban Sinha, Kaushik Sen, Amitabh Sur, Silima Subhasnigdha Tarenia. Diagnosis and management of type 3c diabetes– a consensus statement by Endocrine Society of Bengal. AACE Endocrinology and Diabetes 2026; doi: 10.1016/j.aed.2026.09.020
|
| 17 |
Giovanna Muscogiuri, Guendalina Del Vecchio, Luca Colangeli, Valeria Guglielmi, Paolo Sbraccia, Annamaria Colao. Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer. Internal and Emergency Medicine 2026; doi: 10.1007/s11739-026-04458-z
|
| 18 |
Mark Ayoub, Carol Faris, Tajana Juranovic, Harleen Chela, Ebubekir Daglilar. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study. Cancers 2024; 16(9) doi: 10.3390/cancers16091625
|
| 19 |
Yuxin Wang, Lu Xie, Ye Gu, Hangbin Jin, Jianfeng Yang, Qiang Liu, Xiaofeng Zhang. Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-13976-6
|
| 20 |
Ahmed S. Kenawy, Yi-Shao Liu, Ayobami Aiyeolemi, Godwin Okoye, Chanhyun Park. Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis. Therapeutic Advances in Drug Safety 2025; 16 doi: 10.1177/20420986251335214
|